Sumbul Ali1, Ji-an Chen, Jose M Garcia. 1. aDivision of Diabetes, Endocrinology and Metabolism, MCL, Center for Translational Research in Inflammatory Diseases, Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas, USA bDepartment of Environmental Hygiene, College of Preventive Medicine, Third Military Medical University, Chongqing, China cDept of Molecular and Cell Biology and Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA *Sumbul Ali and Ji-an Chen contributed equally to the writing of this article.
Abstract
PURPOSE OF REVIEW: Cachexia is a devastating complication of cancer for which there is no approved treatment. Here we review the clinical development of ghrelin and ghrelin mimetics (also known as growth hormone secretagogues or GHS) for cancer cachexia treatment. RECENT FINDINGS: Ghrelin, a novel hormone known to increase appetite, lean and fat mass, and growth hormone secretion, is being developed as a therapeutic option for cancer anorexia-cachexia syndrome (CACS). Recent animal studies suggest that it may also decrease inflammation and that some of its effects may be independent of its only known receptor, the GHS receptor-1a.Clinical studies recently have shown that administration of ghrelin or GHS improves appetite and quality of life as assessed by questionnaires. Weight gain, increased food intake and better tolerance to chemotherapy have also been reported. This treatment appears to be safe and well tolerated. SUMMARY: Ghrelin and GHS have the potential to effectively prevent or reverse CACS. Preliminary studies show improvements in weight stabilization and appetite with short-term usage. Further studies are required to fully characterize the role of ghrelin and GHS for the treatment of CACS and to establish the safety of this approach.
PURPOSE OF REVIEW: Cachexia is a devastating complication of cancer for which there is no approved treatment. Here we review the clinical development of ghrelin and ghrelin mimetics (also known as growth hormone secretagogues or GHS) for cancer cachexia treatment. RECENT FINDINGS:Ghrelin, a novel hormone known to increase appetite, lean and fat mass, and growth hormone secretion, is being developed as a therapeutic option for cancer anorexia-cachexia syndrome (CACS). Recent animal studies suggest that it may also decrease inflammation and that some of its effects may be independent of its only known receptor, the GHS receptor-1a.Clinical studies recently have shown that administration of ghrelin or GHS improves appetite and quality of life as assessed by questionnaires. Weight gain, increased food intake and better tolerance to chemotherapy have also been reported. This treatment appears to be safe and well tolerated. SUMMARY:Ghrelin and GHS have the potential to effectively prevent or reverse CACS. Preliminary studies show improvements in weight stabilization and appetite with short-term usage. Further studies are required to fully characterize the role of ghrelin and GHS for the treatment of CACS and to establish the safety of this approach.
Authors: A Asakawa; A Inui; T Kaga; H Yuzuriha; T Nagata; N Ueno; S Makino; M Fujimiya; A Niijima; M A Fujino; M Kasuga Journal: Gastroenterology Date: 2001-02 Impact factor: 22.682
Authors: A M Wren; L J Seal; M A Cohen; A E Brynes; G S Frost; K G Murphy; W S Dhillo; M A Ghatei; S R Bloom Journal: J Clin Endocrinol Metab Date: 2001-12 Impact factor: 5.958
Authors: Jose M Garcia; Thomas Scherer; Ji-an Chen; Bobby Guillory; Anriada Nassif; Victor Papusha; Joanna Smiechowska; Mark Asnicar; Christoph Buettner; Roy G Smith Journal: Endocrinology Date: 2013-07-05 Impact factor: 4.736
Authors: P Cassoni; M Papotti; C Ghè; F Catapano; A Sapino; A Graziani; R Deghenghi; T Reissmann; E Ghigo; G Muccioli Journal: J Clin Endocrinol Metab Date: 2001-04 Impact factor: 5.958
Authors: A M Wren; C J Small; H L Ward; K G Murphy; C L Dakin; S Taheri; A R Kennedy; G H Roberts; D G Morgan; M A Ghatei; S R Bloom Journal: Endocrinology Date: 2000-11 Impact factor: 4.736
Authors: F Broglio; F Boutignon; A Benso; C Gottero; F Prodam; E Arvat; C Ghè; F Catapano; A Torsello; V Locatelli; G Muccioli; D Boeglin; V Guerlavais; J A Fehrentz; J Martinez; E Ghigo; R Deghenghi Journal: J Endocrinol Invest Date: 2002-09 Impact factor: 4.256
Authors: Sharmilee Gnanapavan; Blerina Kola; Stephen A Bustin; Damian G Morris; Patrick McGee; Peter Fairclough; Satya Bhattacharya; Robert Carpenter; Ashley B Grossman; Márta Korbonits Journal: J Clin Endocrinol Metab Date: 2002-06 Impact factor: 5.958
Authors: Aleksandra Matuszyk; Dagmara Ceranowicz; Zygmunt Warzecha; Piotr Ceranowicz; Krzysztof Fyderek; Krystyna Gałązka; Jakub Cieszkowski; Joanna Bonior; Jolanta Jaworek; Małgorzata Pihut; Artur Dembiński Journal: Biomed Res Int Date: 2015-12-02 Impact factor: 3.411
Authors: Marie Sjögren; Ana I Duarte; Andrew C McCourt; Liliya Shcherbina; Nils Wierup; Maria Björkqvist Journal: Sci Rep Date: 2017-10-24 Impact factor: 4.379